• Alias: EMD 72000
    • A humanized IgG1 EGFR monoclonal antibody that binds to EGFR with high affinity
    • Phase 2 trial in patients with platinum-resistant ovarian and primary peritoneal malignancies
    • Recommended dose: 1,600 mg weekly IV infusion
    • Half-life: 4 to 7 days (at recommended dose)
    • Common side effects: Acneiform skin effects, epidermolysis, nail bed infection, conjunctivitis, headache, diarrhea, fever, dry skin, fatigue
    (Vanhoefer et al., 2004)
    Other topics in Targeted and Immunotherapy Agents